SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCity Lon Inv Regulatory News (CLIG)

Share Price Information for City Lon Inv (CLIG)

Share Price is delayed by 15 minutes
Get Live Data
443.00    10.00 (2.31%)
Bid:
440.00
Ask:
443.00
Spread: 3.00 (0.682%)
Market Cap: £218.72m
CLIG Live PriceLast checked at - London Stock Exchange

Intraday City Lon Inv Share Chart

Trading Update

14 Jan 2020 07:00

RNS Number : 6507Z
City of London Investment Group PLC
14 January 2020
 

 

City of London Investment Group PLC

14 January 2020



CITY OF LONDON INVESTMENT GROUP PLC

("City of London", "the Group" or "the Company")

 

FUNDS UNDER MANAGEMENT AS AT 31 December 2019,

TRADING UPDATE

 

City of London (LSE: CLIG), a leading specialist asset management group offering a range of institutional products investing in closed-end funds, announces that as at 31 December 2019, FuM were US$6 billion (£4.5 billion). This compares with US$5.4 billion (£4.3 billion) at the Company's year-end on 30 June 2019. A breakdown by strategy follows:

 

 

FuM ($mn)

 

 

 

Strategy Index

 

 

 

 

 

 

 

 

 

 

 

 

 

Dec-19

Jun-19

%

 

Net

 

 

 

%

 

(estimate)

inc/dec

 

Flows

 

 

 

inc/dec

EM

4,429

4,221

5%

 

(118)

 

MSCI EM

 

7%

DEV

1,109

729

52%

 

272

 

MSCI ACWI

 

7%

Opportunistic Value

270

233

16%

 

20

 

ACWI/Barclays Global Agg

 

5%

Frontier

206

206

0%

 

8

 

S&P Frontier 150

 

0%

 

6,014

5,389

 

 

182

 

 

 

 

 Excludes seed investments

 

The EM and International Developed strategies outperformed, driven by narrower discounts, positive country allocation and good NAV performance. The Opportunistic Value Strategy outperformed led by good NAV performance and significant discount narrowing. The Frontier strategy underperformed due primarily to negative country allocation and discount widening.

 

During the period under review, the Developed strategies recorded net inflows of $272 million. The EM strategies saw net outflows of $118 million. We have to date received notification of circa $200 million of net inflows in aggregate across all strategies, which we expect to fund over the next quarter.

 

With regard to business development, the Group continues to maintain an active pipeline across all of its major CEF offerings with an increased interest in the diversification CEF strategies. 

 

Operations

 

The Group's income currently accrues at a weighted average rate of approximately 75 basis points of FuM, net of third party commissions. "Fixed" costs are c£1.1 million per month, and accordingly the current run-rate for operating profit, before profit-share of 30% and an EIP charge of 5%, is approximately £1.8 million per month based upon current FuM and a US$/£ exchange rate of US$1.3257 to £1 as at 31 December 2019.

 

The Group estimates the unaudited profit before taxation for the six months ended 31 December 2019 to be approximately £6.3 million, which compares with £5.2 million for the equivalent period to 31 December 2018.

 

The Company is currently in a close period which will end with the publication of results for the six months ended 31 December 2019 on 17 February 2020.

 

Dividend

 

In recognition of the improved results and having regard to the current dividend cover policy the Board has decided to increase the interim dividend by 1p to 10p per share, which will be paid on 20 March 2020 to shareholders registered at the close of business on 6 March 2020 (2019: 9 pence).

 

Template

 

Please see the attached graph which is based on the following assumptions and includes the estimated quarterly cost of the dividend:

 

http://www.rns-pdf.londonstockexchange.com/rns/6507Z_1-2020-1-13.pdf

 

Key assumptions:

 

(June 2019 comparatives in Italics)

 

-

Starting point Current FuM (end December 2019)

-

Net increase for the remainder of this financial year (straight-lined to June 2020):

- emerging market CEF strategy zero (zero)

- non-emerging market CEF strategies US$250 (US$250m over the full year)

-

Net increase in 2020/2021 (straight-lined to June 2021):

- emerging market CEF strategy zero

- non-emerging market CEF strategies US$250m

-

Operating margin adjusted monthly for change in product mix and commission run-off

-

Market growth: 0%

-

Overheads for 2019/20: no increase on 2018/2019 (0%)

-

Overheads for 2020/21: +3% compared with 2018/2019

-

EIP cost for 2019/20: 5% of operating profit (5%)

-

EIP cost for 2020/21: n/a now falls within 30% profit-share

-

Corporation tax based on an estimated average rate of 21% (21%)

-

Exchange rate assumed to be £1/$1.31 for entire period (£1/US$1.27)

-

Number of CLIG Shares in issue (26.6m) less those held by the ESOP Trust (1.7m) as at 31 December 2019 (26.6 m CLIG shares in issue less 1.5m ESOP Trust holding)

 

For further information, please visit http://www.citlon.co.uk/ or contact:

 

Tom Griffith, CEO

City of London Investment Group PLC

Tel: 001-610-380-0435

 

Martin Green

Zeus Capital Limited

Financial Adviser & Broker

Tel: +44 (0)20 3829 5000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTSFSFMDESSESF
Date   Source Headline
22nd Sep 201711:08 amRNSHolding(s) in Company
18th Sep 20177:00 amRNSFinal Results
8th Sep 20177:53 amRNSDirector/PDMR Shareholding
31st Aug 20174:00 pmRNSOpen letter to the board of icapital.biz Berhad
20th Jul 20176:22 pmRNSHolding(s) in Company
19th Jul 20177:00 amRNSTrading Update
13th Jul 20176:15 pmRNSHolding(s) in Company
13th Jul 20177:00 amRNSChange of announcement date
13th Jun 20174:26 pmRNSBoard Changes
26th May 20173:49 pmRNSDirector/PDMR Shareholding
25th May 20172:12 pmRNSDirector/PDMR Shareholding
22nd May 201712:56 pmRNSHolding(s) in Company
8th May 20176:03 pmRNSShare Buyback and Total Voting Rights
26th Apr 20173:37 pmRNSHolding(s) in Company
18th Apr 20171:56 pmRNSDirector/PDMR Shareholding
11th Apr 20177:00 amRNSTrading Update
3rd Apr 201712:42 pmRNSHolding(s) in Company
24th Mar 20172:28 pmRNSHolding(s) in Company
21st Mar 20175:20 pmRNSHolding(s) in Company
22nd Feb 20171:40 pmRNSDirector/PDMR Shareholding
22nd Feb 20171:37 pmRNSDirector/PDMR Shareholding
20th Feb 20177:46 amRNSHALF YEAR RESULTS TO 31ST DECEMBER 2016
24th Jan 20173:24 pmRNSHardman Research:Q2 statement robust profitability
17th Jan 20177:00 amRNSFunds Under Management - Trading Update
24th Nov 20163:42 pmRNSDirector/PDMR Shareholding
19th Oct 201611:15 amRNSAGM resolutions
17th Oct 20165:49 pmRNSResult of AGM
13th Oct 20163:05 pmRNSDirector/PDMR Shareholding
11th Oct 20165:13 pmRNSHolding(s) in Company
11th Oct 20162:51 pmRNSDirector/PDMR Shareholding
10th Oct 20167:46 amRNSAGM Trading Update - 1st Qtr Funds under Mgmt
15th Sep 20169:46 amRNSLetter to icapital.biz Berhad
14th Sep 20169:32 amRNSHardman Report: Exchange rate moves give big boost
12th Sep 20167:00 amRNSFINAL RESULTS FOR THE YEAR TO 30TH JUNE 2016
18th Jul 20167:00 amRNSTrading Update
1st Jul 20167:00 amRNSBlock listing cancellation & block listing return
30th Jun 20164:40 pmRNSSecond Price Monitoring Extn
30th Jun 20164:35 pmRNSPrice Monitoring Extension
23rd Jun 20165:55 pmRNSDirector/PDMR Shareholding
14th Apr 201612:38 pmRNSHardman & Co Issues Research Report
22nd Feb 201611:18 amRNSDirector/PDMR Shareholding
15th Feb 20167:00 amRNSHalf Yearly Report
5th Feb 20164:40 pmRNSSecond Price Monitoring Extn
5th Feb 20164:35 pmRNSPrice Monitoring Extension
29th Jan 20164:41 pmRNSSecond Price Monitoring Extn
29th Jan 20164:35 pmRNSPrice Monitoring Extension
27th Jan 20164:40 pmRNSSecond Price Monitoring Extn
27th Jan 20164:35 pmRNSPrice Monitoring Extension
13th Jan 20169:57 amRNSHardman Issues Research Report
12th Jan 20167:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.